As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2022 about Ethical Considerations for Clinical Investigations of Medical Products Involving Children: Draft Guidance for Industry can be found below.